Catalent Inc. started a $200 million capital investment program to expand its biologics manufacturing capacity and capabilities.
Under the three-year investment program, Catalent will increase the mammalian cell culture capacity of its Madison, Wis.-based facility by building two new suites. The company expects to complete the construction by mid-2021, resulting in a more than doubled commercial biomanufacturing capacity.
The company will also extend its Bloomington, Ind.-based site by 79,000 square feet to boost the facility's fill and finish capacity. In December 2018, Catalent invested $14 million to expand the biologics packaging capabilities of the Bloomington facility.
Somerset, N.J.-based Catalent provides advanced delivery technologies and development for drugs, biologics and consumer health products.